Affordable Access

Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients.

Authors
  • Huo, Z
  • Spencer, O
  • Miles, J
  • Johnson, J
  • Holliman, R
  • Sheldon, J
  • Riches, P
Type
Published Article
Journal
Vaccine
Publisher
Elsevier
Publication Date
Mar 12, 2004
Volume
22
Issue
9-10
Pages
1157–1161
Identifiers
PMID: 15003643
Source
Medline
License
Unknown

Abstract

Healthy individuals acquire a comparatively lower concentration of antibody to pneumolysin than to pneumococcal capsular polysaccharides from natural exposure to pneumococcal bacteria. Patients infected by pneumococcal bacteria have lower specific IgG antibody concentrations to both antigens than healthy individuals. These findings support the view that pneumolysin could potentially be used as a vaccine. For enhanced effectiveness, it could be used as a supplement to Pneumovax((R))II rather than as a replacement. The two acquired antibodies, i.e. to pneumolysin and to capsular polysaccharide, could then play their protective roles at different stages in the course of pneumococcal infection, and together contribute to an effective immune defence against Streptococcus pneumoniae.

Report this publication

Statistics

Seen <100 times